Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.
Also called NCT02539966
- Study
- In this atlas
Overview
- Design
- Interventional study; non-randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 272 participants
- Sponsor
- Registry
-
NCT02539966
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Belgium, Brazil, Denmark, France, Germany, Netherlands, Poland
- Registry status
- Completed
Technical summary
Registry record NCT02539966. Non-randomized; no masking; primary purpose treatment. Start 2015-03 (actual); primary completion 2019-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold
- Acronym
- FANTOM II
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
- Lead sponsor
- REVA Medical, Inc.
Record details
- Record id
cardio:ct-nct02539966- Content hash
f772de07cb8c7c4a525323bbf02c1403b3b02b04fc4584b785e5051930b2826f